☆ 4.2 Article

Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article Cell Biology

Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNa and B cell subsets

Hannah F. Bradford et al.

Summary: Systemic lupus erythematosus (SLE) patients often exhibit increased expression of type I interferon (IFN)-regulated genes. In our study of 501 SLE patients, we found that 73 (14%) had autoantibodies against IFN-alpha (anti-IFN-Abs). The presence of neutralizing anti-IFN-Abs in 4.2% of patients correlated with low IFN-alpha protein levels, inhibition of IFN-I downstream gene signatures, and inactive disease score. These neutralizing anti-IFN-Abs were found to play a role in controlling SLE pathogenesis, specifically in regulating B cell populations.

CELL REPORTS MEDICINE (2023)

Add to Collection

Article Immunology

Fulminant Viral Hepatitis in Two Siblings with Inherited IL-10RB Deficiency

Cecilia B. Korol et al.

Summary: Fulminant viral hepatitis (FVH) caused by hepatitis A virus (HAV) is a life-threatening disease. Inherited IL-10RB deficiency and possibly inherited IL-10 and IL-10RA deficiencies confer a predisposition to FVH. Vaccination is recommended for patients with these deficiencies.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Early Treatment with Pegylated Interferon Lambda for Covid-19

Gilmar Reis et al.

Summary: A trial on predominantly vaccinated outpatients with Covid-19 in Brazil and Canada found that the incidence of hospitalization or emergency department visits within 28 days was significantly lower among patients who received a single dose of pegylated interferon lambda compared to those who received a placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Letter Biochemistry & Molecular Biology

Increased type III interferons and NK cell functions in SARS-CoV-2-infected children

Seong Dong Jeong et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Add to Collection

Review Immunology

Type I interferons and SARS-CoV-2: from cells to organisms

Paul Bastard et al.

Summary: Type I interferons play a crucial role in antiviral activity. SARS-CoV-2 infection inhibits the production of interferons in human cells, but exogenous interferons can effectively inhibit viral growth. In animal experiments, deficiencies in interferons lead to more severe diseases, while early administration of interferons improves infection control. In humans, defects in interferons and antibodies against interferons are associated with the severity of COVID-19 pneumonia. Interferons are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.

CURRENT OPINION IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital

Angelique Chauvineau-Grenier et al.

Summary: Recent studies have found that pre-existing autoantibodies neutralizing type I interferons (IFNs) are present in at least 15% of patients with critical COVID-19 pneumonia, increasing the risk of mortality. This highlights the importance of type I IFN immunity in defense against SARS-CoV-2 infection and the usefulness of detecting autoantibodies for patient management.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Review Multidisciplinary Sciences

Human genetic and immunological determinants of critical COVID-19 pneumonia

Qian Zhang et al.

Summary: SARS-CoV-2 infection is generally mild, but in around 10% of cases, it can lead to severe pneumonia and potentially death. Genetic factors, such as inborn errors of type I interferons, and pre-existing auto-antibodies can increase the risk of critical illness. The production of type I interferons is essential for host defense against the virus.

NATURE (2022)

Add to Collection

Article Infectious Diseases

Antibody levels remain high to one-year's follow-up after moderate and severe COVID-19, but not after mild cases

Anne Kallaste et al.

Summary: This study followed 123 COVID-19 patients for one year and found sustained antibody levels in moderate and severe patients after one year. Vaccination of patients with mild disease is important to raise antibody levels to a protective level.

INFECTIOUS DISEASES (2022)

Add to Collection

Article Cell Biology

Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood

Ahto Salumets et al.

Summary: Age-related changes in T-cell populations play an important role in immunosenescence. CD8(+) TEMRA cells and their subsets have characteristics of cellular senescence and increase in older individuals and age-related chronic inflammatory diseases. CD8(+) TEMRA proportions correlate with cytomegalovirus (CMV) antibody levels but not with chronological age. TRANCE/RANKL levels are associated with differentiated T-cell populations, including CD8(+) TEMRA and its CD28(-) subsets. Deep-amplicon bisulfite sequencing can be used to predict CD8(+) TEMRA cell proportions as a biomarker of immunosenescence.

AGING CELL (2022)

Add to Collection

Review Immunology

Human autoantibodies underlying infectious diseases

Anne Puel et al.

Summary: The vast clinical variability in microbial infections can be explained by human genetic and immunological factors, with autoantibodies playing a role in specific infectious diseases.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Add to Collection

Article Immunology

Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C

Peter D. Burbelo et al.

Summary: Autoantibodies against lung antigens and SLE-associated proteins were common in adults with COVID-19, but rare in children. In MIS-C patients, the presence of autoantibodies was largely attributed to IVIG treatment. The decay of IVIG-derived autoantibodies varied among different targets, emphasizing the need for careful monitoring in patients.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Rheumatology

Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α

Alexis Mathian et al.

Summary: This study finds that neutralizing and non-neutralizing autoantibodies against type-I interferons (IFNs-I) are present in patients with systemic lupus erythematosus (SLE). Neutralizing anti-IFN-alpha antibodies are associated with reduced IFN-alpha levels and a decreased likelihood of developing active disease, but they increase the risk of herpes zoster and severe COVID-19 pneumonia. Severe COVID-19 pneumonia in SLE patients is mainly associated with combined neutralization of different IFNs-I.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Deanna M. Santer et al.

Summary: Interferon-lambda is a treatment option for early COVID-19 that enhances innate immunity and accelerates viral clearance without dampening peripheral adaptive immunity. T cell responses are delayed in older adults, but interferon-lambda can overcome this delay.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity

Nikaia Smith et al.

Summary: The interferon response is linked to the severity of SARS-CoV-2 infection and is a crucial part of the immune response to COVID-19. This study stratifies patients based on COVID-19 severity and assesses the interferon response, revealing defective responses in severe infection. The study also highlights the importance of assay variables and confounding factors that affect interferon detection.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Immunology

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

Shohei Eto et al.

Summary: The study revealed that patients with pre-existing autoantibodies to type I interferons have a higher risk of life-threatening COVID-19 pneumonia in the Japanese population.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Critical Care Medicine

Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study

Romain Arrestier et al.

Summary: Auto-antibodies neutralizing type I interferons were found in about 10% of critically ill COVID-19 patients in ICU, but they were not associated with day 28 mortality.

ANNALS OF INTENSIVE CARE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

From rare disorders of immunity to common determinants of infection: Following the mechanistic thread

Jean-Laurent Casanova et al.

Summary: The vast individual clinical variability during infections has long been a puzzle, but studying inborn errors and mechanisms of rare infections has helped identify common genetic or autoimmune determinants of related common infections like tuberculosis and COVID-19. Genetic factors or autoimmune determinants may contribute to the severity of infections, and this rare-to-common genetic and mechanistic approach may be informative for infectious disease research.

CELL (2022)

Add to Collection

Article Allergy

Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19

Hassan Abolhassani et al.

Summary: In most children with preexisting inborn errors of immunity (IEI), genetic causes that affect immune system function were identified. The severity of COVID-19 in these children was high, with a significant mortality rate. Therefore, it is crucial to develop strategies for the prevention and treatment of COVID-19 in children with IEI.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Biology

Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq

Sara E. Vazquez et al.

Summary: Phage immunoprecipitation sequencing (PhIP-seq) is a unbiased method for discovering autoantibodies and studying immune dysregulation in various diseases. This study developed and validated a high throughput extension of PhIP-seq, which can be applied to autoimmune and inflammatory diseases, providing prediction of disease status and detection of autoantigens.

ELIFE (2022)

Add to Collection

Article Engineering, Biomedical

Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries

Joel J. Credle et al.

Summary: Pathogenic autoreactive antibodies associated with severe COVID-19 can be identified using self-assembled genome-scale libraries of full-length proteins covalently coupled to unique DNA barcodes. This method allows for unbiased identification of autoreactive antibodies in plasma samples, and has been successfully used to identify new and known autoreactive antibodies. The cost-effectiveness and simplicity of this method make it suitable for high-throughput analysis of protein-antibody interactions.

NATURE BIOMEDICAL ENGINEERING (2022)

Add to Collection

Article Critical Care Medicine

Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU

Arnaud Fekkar et al.

Summary: This study examined the occurrence of invasive fungal respiratory superinfections in severe COVID-19 patients admitted to five ICUs in France, finding that patients with no underlying immunosuppression seem at low risk of invasive fungal secondary infection.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Immunology

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Ioanna-Evdokia Galani et al.

Summary: Andreakos and colleagues conducted a study comparing patients with COVID-19 and influenza, finding that COVID-19 patients exhibited a dysregulated interferon response with diminished and delayed interferon production compared to flu patients. In COVID-19 patients, pro-inflammatory cytokines were produced before interferons and persisted longer, leading to worsened clinical outcomes.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

Xavier Solanich et al.

Summary: The study found that 9.5% of patients admitted to the ICU for COVID-19 pneumonia in a hospital in Barcelona had neutralizing auto-antibodies against high concentrations of type I IFNs. These patients exhibited abnormal laboratory tests related to the severity of COVID-19, as well as a higher incidence of acute kidney injury.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Jordan J. Feld et al.

Summary: The study investigated the safety and efficacy of peginterferon lambda in treating outpatients with mild-to-moderate COVID-19. Results showed that patients treated with peginterferon lambda had a faster decline in viral RNA and were more likely to clear the virus by day 7 compared to the placebo group.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Immunology

Age-Related Expression of IFN-λ1 Versus IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals

Charly Gilbert et al.

Summary: SARS-CoV-2 infection induces heterogeneous symptoms, with different expression patterns of innate immune molecules in the nasopharyngeal mucosa, suggesting that susceptibility to SARS-CoV-2 may be related to intrinsic differences in mucosal anti-viral innate immunity across age groups.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Jesus Troya et al.

Summary: In severe cases of COVID-19 pneumonia, approximately 10.6% of patients were found to have autoantibodies neutralizing type I IFN, which correlated with increased C-reactive protein levels and decreased lymphocyte counts, possibly increasing the risk of death. Subcutaneous IFN-beta treatment did not seem to improve clinical outcomes.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Paul Bastard et al.

Summary: Patients with biallelic loss-of-function variants of AIRE, suffering from APS-1, produce autoantibodies that neutralize most type I interferons, leading to a significantly increased risk of life-threatening COVID-19 pneumonia. Research has shown that in APS-1 patients with these neutralizing autoantibodies, 86% developed COVID-19 pneumonia.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Diverse functional autoantibodies in patients with COVID-19

Eric Y. Wang et al.

Summary: COVID-19 patients show increased autoantibody reactivities against immunomodulatory proteins, which may affect immune function and lead to different clinical outcomes.

NATURE (2021)

Add to Collection

Review Rheumatology

Interferon lambda in inflammation and autoimmune rheumatic diseases

Rishi R. Goel et al.

Summary: Interferons are potent antiviral cytokines that modulate immunity, with type III interferons having complex effects on innate and adaptive immune responses and potential pathogenic roles in autoimmune diseases. This review provides an overview of IFN lambda in rheumatic diseases and discusses therapeutic strategies targeting them.

NATURE REVIEWS RHEUMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan et al.

Summary: A randomized, single-blind, placebo-controlled trial on 120 outpatients with mild to moderate COVID-19 showed that a single subcutaneous dose of Peginterferon Lambda-1a (Lambda) did not shorten the duration of SARS-CoV-2 viral shedding or improve symptoms. The treatment was well tolerated but did not have a significant impact on the outcomes of the patients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The interferon landscape along the respiratory tract impacts the severity of COVID-19

Benedetta Sposito et al.

Summary: The study found that high levels of IFN-III, and to a lesser extent IFN-I, in the upper airways of COVID-19 patients with high viral burden indicate reduced disease risk or severity. Specific IFN-III members denote patients with a mild pathology and protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while IFNs in the lower airways of patients with severe COVID-19 are associated with increased apoptosis and decreased proliferation. The data demonstrate a dynamic production of IFNs in SARS-CoV-2-infected patients and show opposing roles of IFNs at distinct anatomical sites.

CELL (2021)

Add to Collection

Article Cell Biology

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

Michael S. Abers et al.

Summary: This study compared clinical outcomes between patients with neutralizing type-I interferon autoantibodies (AAbs) and those without AAbs during hospitalization for COVID-19, revealing that patients with AAbs were more likely to be admitted to the intensive care unit with delayed viral clearance, although their survival was not adversely affected.

IMMUNOLOGY AND CELL BIOLOGY (2021)

Add to Collection

Article Cell Biology

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Monique G. P. van der Wijst et al.

Summary: Autoantibodies against type I interferons have been identified in some patients with critical COVID-19, with higher prevalence in severe cases. The longitudinal dynamics and functional effects of these antibodies on circulating leukocytes remain unclear.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Immunology

Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study)

Piia Jogi et al.

Summary: The study found that the seroprevalence of SARS-CoV-2 in Estonia was low during the COVID-19 pandemic, even in the hotspot region, indicating that the majority of the population may be susceptible to the virus. Furthermore, focusing solely on respiratory symptoms may delay the accurate diagnosis of SARS-CoV-2 infection.

VACCINE (2021)

Add to Collection

Article Multidisciplinary Sciences

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Sarah Esther Chang et al.

Summary: In hospitalized COVID-19 patients, approximately 50% have detectable autoantibodies primarily targeting autoantigens associated with rare disorders. Additionally, a subset of autoantibodies develop de novo following SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths

Paul Bastard et al.

Summary: Autoantibodies neutralizing interferons are present in a significant percentage of critical COVID-19 patients, especially in older individuals, and their prevalence increases with age.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

X-linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life-threatening COVID-19

Takaki Asano et al.

Summary: A study revealed that rare X-linked TLR7 variants were found in 16 unrelated male individuals with critical COVID-19 pneumonia out of a cohort of 1202 male patients. No such variants were detected in 331 asymptomatic or mildly infected male individuals.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients

David Goncalves et al.

Summary: The study found that some critically ill COVID-19 patients have autoantibodies against IFN-I, which may impair the immune response. However, patients with neutralizing anti-IFN-alpha(2) autoantibodies showed no significant differences in clinical characteristics or outcomes.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

COVID-19 and emerging viral infections: The case for interferon lambda

Ludmila Prokunina-Olsson et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Biology

Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq

Sara E. Vazquez et al.

ELIFE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of SARS-CoV-2 by type I and type III interferons

Ulrike Felgenhauer et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Virology

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Abigail Vanderheiden et al.

JOURNAL OF VIROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Jerome Hadjadj et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Megan L. Stanifer et al.

CELL REPORTS (2020)

Add to Collection

Article Multidisciplinary Sciences

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Review Public, Environmental & Occupational Health

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

Andrew T. Levin et al.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Robbert Boudewijns et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Immunology

Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control

Evangelos Andreakos et al.

CURRENT OPINION IN IMMUNOLOGY (2019)

Add to Collection

Review Immunology

Shared and Distinct Functions of Type I and Type III Interferons

Helen M. Lazear et al.

IMMUNITY (2019)

Add to Collection

Article Virology

Interferon-Stimulated Genes: What Do They All Do?

John W. Schoggins

ANNUAL REVIEW OF VIROLOGY, VOL 6, 2019 (2019)

Add to Collection

Review Immunology

Lambda interferons in immunity and autoimmunity

Stelios Vlachiotis et al.

JOURNAL OF AUTOIMMUNITY (2019)

Add to Collection

Review Immunology

Interferon-λ orchestrates innate and adaptive mucosal immune responses

Liang Ye et al.

NATURE REVIEWS IMMUNOLOGY (2019)

Add to Collection

Article Immunology

Type III interferon is a critical regulator of innate antifungal immunity

Vanessa Espinosa et al.

SCIENCE IMMUNOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies

Steffen Meyer et al.

CELL (2016)

Add to Collection

Article Immunology

Interferon lambda 4 expression is suppressed by the host during viral infection

MeeAe Hong et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

Age-related profiling of DNA methylation in CD8+T cells reveals changes in immune response and transcriptional regulator genes

Liina Tserel et al.

SCIENTIFIC REPORTS (2015)

Add to Collection

Article Immunology

Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice

J. Kaerner et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)

Add to Collection

Article Genetics & Heredity

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

Ludmila Prokunina-Olsson et al.

NATURE GENETICS (2013)

Add to Collection

Article Hematology

Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia

Peter D. Burbelo et al.

BLOOD (2010)

Add to Collection

Article Medicine, General & Internal

Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1

Anthony Meager et al.

PLOS MEDICINE (2006)

Add to Collection

Article Immunology

IL-28, IL-29 and their class II cytokine receptor IL-28R

P Sheppard et al.

NATURE IMMUNOLOGY (2003)

Add to Collection

Article Immunology

IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex

SV Kotenko et al.

NATURE IMMUNOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.